Inflammatory myofibroblastic tumor as a second neoplasm after Wilms tumor

Authors

Michael V. Ortiz, Childrens National Health System
Christopher T. Rossi, Childrens National Health System
D. Ashley Hill, Childrens National Health System
Phillip C. Guzzetta, Childrens National Health System
Faisal Qureshi, Childrens National Health System
Jeffrey S. Dome, Childrens National Health System

Document Type

Journal Article

Publication Date

1-1-2015

Journal

Pediatric Blood and Cancer

Volume

62

Issue

6

DOI

10.1002/pbc.25345

Keywords

ALK; Inflammatory myofibroblastic tumor; Second neoplasm; Wilms tumor

Abstract

© 2014 Wiley Periodicals, Inc. We report two survivors of Wilms tumor (WT) who developed inflammatory myofibroblastic tumor (IMT). The first patient had IMT in the mainstem bronchus 1 year after WT therapy that included vincristine, dactinomycin, doxorubicin (VDA) and whole lung radiation therapy (XRT). The second patient had IMT in the cecum 7 years after WT therapy consisting of VDA and abdominal XRT. The unlikely co-occurrence of WT and IMT suggests a genetic link between these tumors or that IMT can arise as a complication of cancer therapy. IMT should be considered in WT survivors who develop secondary tumors, especially at unusual sites.

APA Citation

Ortiz, M., Rossi, C., Hill, D., Guzzetta, P., Qureshi, F., & Dome, J. (2015). Inflammatory myofibroblastic tumor as a second neoplasm after Wilms tumor. Pediatric Blood and Cancer, 62 (6). http://dx.doi.org/10.1002/pbc.25345